Leukaemia Foundation

Change Your Location:

2015 Research Awards

In our 2015 round of grants, the Leukaemia Foundation is investing almost $4 million of donated funds in an additional 14 promising blood cancer research projects. These awards, to researchers, students and institutions working at the frontiers of medicine in Melbourne, Sydney, Brisbane and Adelaide, are in “the hottest areas of research in haematology at the moment”, according to our Head of Research & Advocacy, Dr Anna Williamson.

Together with 35 continuing grants awarded in previous years, this takes the total number of reserach projects currently funded by the Leukaemia Foundation, to 49.



Dr Colm Keane

Dr Colm Keane is developing a new prognostic test to predict lymphoma patients who will benefit from a new type of cancer treatment called ‘immune checkpoint therapy’.

Read More about: Dr Colm Keane

Professor Stephen Mulligan

Professor Stephen Mulligan, is leading an Australian clinical trial to investigate a potential new treatment schedule for older patients with chronic lymphocytic leukaemia (CLL).

Read More about: Professor Stephen Mulligan

Dr Omer Gilan

Combining therapies targeting epigenetic* mutations in cancer cells could provide a new strategy for treating acute myeloid leukaemia (AML), according to Dr Omer Gilan.

Read More about: Dr Omer Gilan

Dr Andrea Newbold

Dr Andrea Newbold is using sophisticated models of acute myeloid leukaemia (AML) to develop new combination treatment regimens as well as to understand the molecular interplay between genetic and epigenetic changes driving this blood cancer.

Read More about: Dr Andrea Newbold

Mr Dean Sydney Tyler

In this PhD project, Dean is using new techniques to discover how the anti-cancer drug, azacitidine (Vidaza®) interacts within cells. Azacitidine is the only drug available for treating myelodysplastic syndrome (MDS), and is also used to treat several other cancers including chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML).

Read More about: Mr Dean Sydney Tyler

Ms Rebecca Austin

QIMR Berghofer Medical Research Institute (QIMRB) researchers believe it may be possible to treat acute myeloid leukaemia (AML) with new immune-based anti-cancer therapies that enlist the immune system to kill cancer cells.

Read More about: Ms Rebecca Austin

Miss Rebecca Delconte

Rebecca Delconte is investigating the role of natural killer (NK) cells in leukaemia. These specialised immune cells have the ability to detect and kill cancerous cells. However, leukaemia cells are able to evade NK cell death.

Read More about: Miss Rebecca Delconte

Mr Ankit Dutta

PhD candidate Ankit Dutta is identifying important genetic changes involved in the transition of MGUS to myeloma.

Read More about: Mr Ankit Dutta

Dr Pasquale Fedele

To better understand how myeloma develops, Dr Pasquale Fedele is studying two genes – PRDM1 and X-box binding protein 1 (XBP1) – that are important for normal plasma cell development and function.

Read More about: Dr Pasquale Fedele

Dr Stephanie Grabow

Researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI) are investigating new avenues to develop a new anti-cancer treatment for lymphoma and leukaemia. One of these avenues is to target MCL-1, a protein that is critical for the survival of many cell types.

Read More about: Dr Stephanie Grabow

Ms Margs Brennan

Margs Brennan is assessing a potential new anti-cancer drug that selectively targets and inhibits a protein called MCL-1 (myeloid cell leukaemia 1).

Read More about: Ms Margs Brennan

Dr Ming-Celine Dubosq

A new, cell-based therapy for treating blood cancers could offer hope for Australians with myeloma.

Read More about: Dr Ming-Celine Dubosq

Australasian Leukaemia & Lymphoma Group Discovery Centre

The Leukaemia Foundation is contributing $550,000 over three years to the running costs of Australia’s only specialised blood cancer tissue bank. The ALLG Discovery Centre (formerly the ALLG Tissue Bank) stores a growing library of samples collected from Australian patients with leukaemia, lymphoma, myeloma or related blood disorders

Read More about: Australasian Leukaemia & Lymphoma Group Discovery Centre